

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Ni et al.

Application Serial No.: 09/109,864

Filed: July 6, 1998

For: GALECTIN 11



Group Art Unit: 1646

Examiner: Ulm, J.

Attny Docket No.: PF354P1

#6  
J.G.J.  
12/13/99

**INFORMATION DISCLOSURE STATEMENT**  
**PURSUANT TO 37 CFR 1.97(b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to reference B1 listed on the attached Form PTO 1449. A copy of cited references B1 and C1-C11 are enclosed. Full references corresponding to C4 and C5 are forthcoming.

The relevancy of reference B1 to the instant application can be found in the sequence listing and Figures 1-4 of the Japanese language document.

Copies of references B2-B7 and C12-C31 were submitted by Applicants or cited by the Examiner in connection with U. S. Patent Application Serial No. 09/010,146, filed January 21, 1998, to which the instant application claims priority under 35 U.S.C. § 120. Pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the file of United States Patent Application Serial No. 09/010,146 for copies of references B2-B7 and C12-C31.

Applicants also wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clones of the above-captioned application are related to:

- (a) SEQ ID NO:7117 in copending U.S. Patent Application No. 08/276,163; and
- (b) SEQ ID NO:1612 in copending U.S. Patent Application No. 60/118,775.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The Assistant Commissioner is authorized to charge any fee deemed necessary in connection with this submission to our Deposit Account No. 08-3425.

Respectfully submitted,

Dated: 12-7-99



Michelle S. Marks (Reg. No. 41,971)  
Attorney for Applicants

Human Genome Sciences, Inc.  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (301) 610-5761

Enclosures  
MSM/mbp

